Article
Washington, DC-Drug companies will be limited to one 30-month stay of a generic drug's entry into the market under new FDA rules introduced by the federal Health and Human Services department.
Making the grade: FDA approves first biosimilar product for retinal diseases
Advancement in TED treatment is a bright spot
Comparable conscious sedation methods address individual patient needs
Investigators uncover health care disparities among US patients
Investigators zoom in on future of dry eye treatment
Analyzing opioid prescription patterns of US retina specialists